Stock of the Day for March 17, 2025

GSK Stock Report

GSK
GSK 90-day performance NYSE:GSK GSK
Current Price
$37.15
-1.83 (-4.68%)
(As of 03:59 PM ET)
30 Day Performance
-4.56%
  
  
90 Day Performance
-4.85%
  
  
1 Year Performance
-4.23%
  
  
Market Capitalization
$75.83B
P/E Ratio
19.15
Dividend Yield
4.58%
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK Company Calendar

MAY. 16, 2025
Ex-Dividend for 7/10 Dividend
JUL. 10, 2025
Dividend Payable
JUL. 30, 2025
Last Earnings
JUL. 31, 2025
Today
DEC. 31, 2025
Fiscal Year End

Recent GSK News

GSK (NYSE:GSK) Updates FY 2025 Earnings Guidance
GSK plc (GSK) Q2 2025 Earnings Call Transcript
GSK in talks with Trump administration on U.S. drug pricing, CEO says
GSK expects annual sales and profit at top end of forecast range
GSK Sales, Core Earnings Expected to Edge Lower -- Earnings Preview
This report was written on March 17, 2025 and updated on July 31, 2025. This report first appeared on MarketBeat.com.